NCT05896059View on ClinicalTrials.gov

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab，200mg，D1, intravenous，Q3W；

DRUG

Anlotinib

Anlotinib，12mg，oral administration，QD.

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER